Bank of New York Mellon
VTGN icon

Bank of New York Mellon’s VistaGen Therapeutics VTGN Stock Holding History

Bank of New York Mellon’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-15,171
Closed -$78K – 4322
2023
Q4 		$78K Buy
+15,171
New +$57.4K ﹤0.01% 4125
2023
Q2 		– Sell
-19,303
Closed -$72.2K – 4463
2023
Q1 		$72.2K Hold
19,303
– – ﹤0.01% 4128
2022
Q4 		$59.6K Hold
19,303
– – ﹤0.01% 4211
2022
Q3 		$88K Sell
19,303
-4,502
-19% -$44.6K ﹤0.01% 4223
2022
Q2 		$628K Sell
23,805
-1,823
-7% -$64.4K ﹤0.01% 3451
2022
Q1 		$954K Sell
25,628
-1,478
-5% -$64.4K ﹤0.01% 3351
2021
Q4 		$1.58M Buy
27,106
+7,327
+37% +$477K ﹤0.01% 3132
2021
Q3 		$1.63M Buy
19,779
+4,148
+27% +$360K ﹤0.01% 3116
2021
Q2 		$1.48M Buy
15,631
+13,537
+646% +$1M ﹤0.01% 3190
2021
Q1 		$134K Buy
2,094
+171
+9% +$11.4K ﹤0.01% 4126
2020
Q4 		$112K Buy
+1,923
New +$49.1K ﹤0.01% 4061

Other funds holding VTGN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Bank of New York Mellon's VTGN Position: Q1 2024 in Review

Bank of New York Mellon sold out of VistaGen Therapeutics (VTGN) in Q1 2024, closing a stake of 15,171 shares — an estimated $78K sold.

Bank of New York Mellon first reported a position in VTGN in Q4 2020 and held it in 11 quarters. The position peaked at $1.63M in Q3 2021. 42 funds tracked by Wall St. Rank hold VTGN as of Q1 2024.

  • Bank of New York Mellon reported no remaining VistaGen Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Bank of New York Mellon sold 15,171 VistaGen Therapeutics shares in Q1 2024, an estimated $78K.
  • Bank of New York Mellon first reported a position in VistaGen Therapeutics in Q4 2020 and held it in 11 quarters.
  • Bank of New York Mellon's VistaGen Therapeutics position peaked at $1.63M in Q3 2021.
  • 42 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2024.

Based on Bank of New York Mellon's 13F filing for Q1 2024, filed 25 Apr 2024.